BACKGROUND AND PURPOSE: Immunomodulatory tetracyclines are well-characterized drugs with a pharmacological potential beyond their antibiotic properties. Specifically, minocycline and doxycycline have shown beneficial effects in experimental colitis, although pro-inflammatory actions have also been described in macrophages. Therefore, we aimed to characterize the mechanism behind their effect in acute intestinal inflammation. EXPERIMENTAL APPROACH: A comparative pharmacological study was initially used to elucidate the most relevant actions of immunomodulatory tetracyclines: doxycycline, minocycline and tigecycline; other antibiotic or immunomodulatory drugs were assessed in bone marrow-derived macrophages and in dextran sodium sulfate (DSS)-induced mouse colitis, where different barrier markers, inflammatory mediators, microRNAs, TLRs, and the gut microbiota composition were evaluated. The sequential immune events that mediate the intestinal anti-inflammatory effect of minocycline in DSS-colitis were then characterized. KEY RESULTS: Novel immunomodulatory activity of tetracyclines was identifed; they potentiated the innate immune response and enhanced resolution of inflammation. This is also the first report describing the intestinal anti-inflammatory effect of tigecycline. A minor therapeutic benefit seems to derive from their antibiotic properties. Conversely, immunomodulatory tetracyclines potentiated macrophage cytokine release in vitro, and while improving mucosal recovery in colitic mice, they up-regulated Ccl2, miR-142, miR-375 and Tlr4. In particular, minocycline initially enhanced IL-1β, IL-6, IL-22, GM-CSF and IL-4 colonic production and monocyte recruitment to the intestine, subsequently increasing Ly6C- MHCII+ macrophages, Tregs and type 2 intestinal immune responses. CONCLUSIONS AND IMPLICATIONS: Immunomodulatory tetracyclines potentiate protective immune pathways leading to mucosal healing and resolution, representing a promising drug reposition strategy for the treatment of intestinal inflammation.
BACKGROUND AND PURPOSE: Immunomodulatory tetracyclines are well-characterized drugs with a pharmacological potential beyond their antibiotic properties. Specifically, minocycline and doxycycline have shown beneficial effects in experimental colitis, although pro-inflammatory actions have also been described in macrophages. Therefore, we aimed to characterize the mechanism behind their effect in acute intestinal inflammation. EXPERIMENTAL APPROACH: A comparative pharmacological study was initially used to elucidate the most relevant actions of immunomodulatory tetracyclines: doxycycline, minocycline and tigecycline; other antibiotic or immunomodulatory drugs were assessed in bone marrow-derived macrophages and in dextran sodium sulfate (DSS)-induced mousecolitis, where different barrier markers, inflammatory mediators, microRNAs, TLRs, and the gut microbiota composition were evaluated. The sequential immune events that mediate the intestinal anti-inflammatory effect of minocycline in DSS-colitis were then characterized. KEY RESULTS: Novel immunomodulatory activity of tetracyclines was identifed; they potentiated the innate immune response and enhanced resolution of inflammation. This is also the first report describing the intestinal anti-inflammatory effect of tigecycline. A minor therapeutic benefit seems to derive from their antibiotic properties. Conversely, immunomodulatory tetracyclines potentiated macrophage cytokine release in vitro, and while improving mucosal recovery in colitic mice, they up-regulated Ccl2, miR-142, miR-375 and Tlr4. In particular, minocycline initially enhanced IL-1β, IL-6, IL-22, GM-CSF and IL-4 colonic production and monocyte recruitment to the intestine, subsequently increasing Ly6C- MHCII+ macrophages, Tregs and type 2 intestinal immune responses. CONCLUSIONS AND IMPLICATIONS: Immunomodulatory tetracyclines potentiate protective immune pathways leading to mucosal healing and resolution, representing a promising drug reposition strategy for the treatment of intestinal inflammation.
Authors: Natividad Garrido-Mesa; Pilar Utrilla; Mónica Comalada; Pedro Zorrilla; José Garrido-Mesa; Antonio Zarzuelo; María Elena Rodríguez-Cabezas; Julio Gálvez Journal: Biochem Pharmacol Date: 2011-09-16 Impact factor: 5.858
Authors: Ryan Ungaro; Charles N Bernstein; Richard Gearry; Anders Hviid; Kaija-Leena Kolho; Matthew P Kronman; Souradet Shaw; Herbert Van Kruiningen; Jean-Frédéric Colombel; Ashish Atreja Journal: Am J Gastroenterol Date: 2014-09-16 Impact factor: 10.864
Authors: Yan Zheng; Patricia A Valdez; Dimitry M Danilenko; Yan Hu; Susan M Sa; Qian Gong; Alexander R Abbas; Zora Modrusan; Nico Ghilardi; Frederic J de Sauvage; Wenjun Ouyang Journal: Nat Med Date: 2008-02-10 Impact factor: 53.440
Authors: Li Liu; Hope L Johnson; Simon Cousens; Jamie Perin; Susana Scott; Joy E Lawn; Igor Rudan; Harry Campbell; Richard Cibulskis; Mengying Li; Colin Mathers; Robert E Black Journal: Lancet Date: 2012-05-11 Impact factor: 79.321
Authors: Nadine Wittkopf; Geethanjali Pickert; Ulrike Billmeier; Mousumi Mahapatro; Stefan Wirtz; Eva Martini; Moritz Leppkes; Markus Friedrich Neurath; Christoph Becker Journal: PLoS One Date: 2015-03-23 Impact factor: 3.240
Authors: Joanne C Masterson; Eóin N McNamee; Sophie A Fillon; Lindsay Hosford; Rachel Harris; Shahan D Fernando; Paul Jedlicka; Ryo Iwamoto; Elizabeth Jacobsen; Cheryl Protheroe; Holger K Eltzschig; Sean P Colgan; Makoto Arita; James J Lee; Glenn T Furuta Journal: Gut Date: 2014-09-10 Impact factor: 23.059
Authors: J Garrido-Mesa; A Rodríguez-Nogales; F Algieri; T Vezza; L Hidalgo-Garcia; M Garrido-Barros; M P Utrilla; F Garcia; N Chueca; M E Rodriguez-Cabezas; N Garrido-Mesa; J Gálvez Journal: Br J Pharmacol Date: 2018-10-15 Impact factor: 8.739
Authors: Qing Hao Miow; Andres F Vallejo; Yu Wang; Jia Mei Hong; Chen Bai; Felicia Sw Teo; Alvin Dy Wang; Hong Rong Loh; Tuan Zea Tan; Ying Ding; Hoi Wah She; Suay Hong Gan; Nicholas I Paton; Josephine Lum; Alicia Tay; Cynthia Be Chee; Paul A Tambyah; Marta E Polak; Yee Tang Wang; Amit Singhal; Paul T Elkington; Jon S Friedland; Catherine Wm Ong Journal: J Clin Invest Date: 2021-08-02 Impact factor: 14.808
Authors: Patricia Diez-Echave; Izaskun Martín-Cabrejas; José Garrido-Mesa; Susana Langa; Teresa Vezza; José M Landete; Laura Hidalgo-García; Francesca Algieri; Melinda J Mayer; Arjan Narbad; Ana García-Lafuente; Margarita Medina; Alba Rodríguez-Nogales; María Elena Rodríguez-Cabezas; Julio Gálvez; Juan L Arqués Journal: Nutrients Date: 2021-05-29 Impact factor: 6.706
Authors: María Jesús Rodríguez-Sojo; Antonio Jesús Ruiz-Malagón; María Elena Rodríguez-Cabezas; Julio Gálvez; Alba Rodríguez-Nogales Journal: Nutrients Date: 2021-03-21 Impact factor: 5.717